About Tumor necrosis factor receptor superfamily member 10D
Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D) is a protein
from Homo sapiens identified by UniProt accession
Q9UBN6, 386 residues long.
MolForge cross-references it against 0 known binders and
96 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 10D |
| UniProt accession | Q9UBN6 |
| Gene | TNFRSF10D |
| Organism | Homo sapiens |
| Length | 386 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (96)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.26
- lung adenocarcinoma · score 0.23
- gastric adenocarcinoma · score 0.23
- endometrial cancer · score 0.23
- urinary bladder cancer · score 0.23
- cutaneous melanoma · score 0.18
- hepatocellular carcinoma · score 0.11
- neoplasm · score 0.09
- neutrophil percentage of leukocytes · score 0.08
- lymphocyte percentage of leukocytes · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UBN6-F1 | alphafold | PREDICTED | 60.96 | — |
Amino-acid sequence (386 residues)
MGLWGQSVPT ASSARAGRYP GARTASGTRP WLLDPKILKF VVFIVAVLLP VRVDSATIPR QDEVPQQTVA PQQQRRSLKE EECPAGSHRS EYTGACNPCT EGVDYTIASN NLPSCLLCTV CKSGQTNKSS CTTTRDTVCQ CEKGSFQDKN SPEMCRTCRT GCPRGMVKVS NCTPRSDIKC KNESAASSTG KTPAAEETVT TILGMLASPY HYLIIIVVLV IILAVVVVGF SCRKKFISYL KGICSGGGGG PERVHRVLFR RRSCPSRVPG AEDNARNETL SNRYLQPTQV SEQEIQGQEL AELTGVTVEL PEEPQRLLEQ AEAEGCQRRR LLVPVNDADS ADISTLLDAS ATLEEGHAKE TIQDQLVGSE KLFYEEDEAG SATSCL
Explore Tumor necrosis factor receptor superfamily member 10D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets